二代测序在活化B细胞样弥漫大B细胞淋巴瘤中的研究进展  

Progress of next generation sequencing in activated B-cell like diffuse large B-cell lymphoma

作　　者：段文静[1] 李玲[1] 张明智[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,450001

出　　处：《白血病．淋巴瘤》2017年第4期249-252,共4页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81570203、81570204）

摘　　要：弥漫大B细胞淋巴瘤（DLBCL）是淋巴瘤中最常见的一种类型,占非霍奇金淋巴瘤的30%~40%,是一组发病机制、临床表现、形态特点、免疫表型、分子亚群及临床预后均具有高度异质性的淋巴瘤.通过识别单核苷酸变异进行基因测序,从基因角度对DLBCL的重新定义,为该病在分子亚型精确诊断和针对性治疗中提供了更加有力的证据支持.Diffuse large B-cell lymphoma （DLBCL）, being the most common lymphoma entity, accounting for 30 % ˉ 40 % of newly diagnosed non-Hodgkin lymphomas, is a kind of highly heterogeneous lymphoma with different pathogenesis, clinical manifestations, morphological characteristics, the immune phenotype, molecular subgroup and clinical outcomes. Gene sequencing of DLBCL has redefined the genetic landscape of the disease by identifying recurrent single nucleotide variants, which provides more powerful evidence to support accurate diagnosis and targeted treatment in DLBCL molecular subtypes.

关 键 词：淋巴瘤 大B-细胞 弥漫性 基因 分子靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]